Fresenius increased its 2013 Senior Credit Agreement by €1.2 billion incremental facilities as a further step to fund the acquisition of IDC Salud Holding S.L.U. (Quironsalud) by Fresenius Helios. A bridge facility of €3.75 billion was already signed in September 2016. The incremental facilities consist of an incremental term loan A of €900 million and an incremental revolving facility of €300 million. The transaction was well received by investors and substantially oversubscribed. More than 40 financial institutions participated.
Moody’s Investors Service has upgraded the corporate credit rating of Fresenius from Ba1 to Baa3 with a stable outlook.
The upgrade reflects Moody's view that Fresenius' business profile has improved over the last years supported by higher business and geographical diversification and increased scale as well as a strong track record of profitable growth and deleveraging post acquisitions.
In January 2015, Standard & Poor’s upgraded the corporate credit rating of Fresenius from previously BB+ to BBB- with a stable outlook.
Fresenius continues to view itself as an active consolidator in its markets and will continue to focus on financing acquisitions primarily with debt.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.